Literature DB >> 31918581

Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?

Ann Marie Navar1, Hillary M Mulder1, Daniel M Wojdyla1, Eric D Peterson1.   

Abstract

Entities:  

Keywords:  PCSK9; approval rates; utilization

Mesh：

Substances：

Year:  2020        PMID： 31918581      PMCID： PMC7039320          DOI： 10.1161/CIRCOUTCOMES.119.006019

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN： 1941-7713


× No keyword cloud information.
  5 in total

1.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah
Journal:  Circulation       Date:  2018-11-10       Impact factor: 29.690

2.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors:  Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

3.  2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

Authors:  Donald M Lloyd-Jones; Pamela B Morris; Christie M Ballantyne; Kim K Birtcher; David D Daly; Sondra M DePalma; Margo B Minissian; Carl E Orringer; Sidney C Smith
Journal:  J Am Coll Cardiol       Date:  2017-09-05       Impact factor: 24.094

4.  Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.

Authors:  Ann Marie Navar; Benjamin Taylor; Hillary Mulder; Eugene Fievitz; Keri L Monda; Anna Fievitz; Juan F Maya; J Antonio G López; Eric D Peterson
Journal:  JAMA Cardiol       Date:  2017-11-01       Impact factor: 14.676

5.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Authors:  Gregory G Schwartz; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Rafael Diaz; Jay M Edelberg; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Guillaume Lecorps; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Kirby Quintero; Matthew T Roe; William J Sasiela; Jean-François Tamby; Pierluigi Tricoci; Harvey D White; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2018-11-07       Impact factor: 91.245
  5 in total
  1 in total

1.  Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report.

Authors:  Angela Dardano; Giuseppe Daniele; Giuseppe Penno; Roberto Miccoli; Stefano Del Prato
Journal:  Front Med (Lausanne)       Date:  2021-07-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.